Glycorex Transplantation AB (publ) is a globally recognized medical technology company headquartered in Lund, Sweden, with a unique know-how in the fields of biologically active carbohydrates and extracorporeal blood treatment. The company has developed a unique medical technology (antigen-specific immunoadsorption) to specifically reduce blood group antibodies and autoantibodies in the blood. Glycorex's focus areas include transplantation, blood transfusion, and autoimmune diseases. The company's own proprietary medical device, Glycosorb® ABO, improves and saves lives by removing the blood group barrier facilitating blood group incompatible transplantation and transfusion. This groundbreaking innovation has garnered global recognition, with over 6,500 successful blood group-incompatible organ transplants performed worldwide since its inception in 2001. Product development and production takes place in the company’s own facility in Lund, Sweden. Glycorex Transplantation AB (publ) has been listed on NGM Main Regulated Equity (Nordic Growth Market) since 2001.